BUSINESS

A look at the homes and property portfolios of some of the biggest names competing for the Mirrorball Trophy this season.

You can be right about the science and still lose every dollar you put in.

That is the hardest lesson in small-cap investing, and it shows up in credit agreements and amendment schedules, not in press releases.

Here is how the game usually works. A young drug company raises money against a future event, an FDA decision, a trial readout, a launch.

Lenders size the loan to the story. You size your position to the same story. Everyone stares at the catalyst date.

The debt has its own date, and it does not care about the catalyst.

A term loan with quarterly amortization and a fixed maturity keeps ticking whether the drug works or not. If the cash runs out before the catalyst arrives, the catalyst still happens. It just belongs to someone else.

That is not a theoretical risk. It happened last month, to a company sitting ten weeks away from the approval it spent years chasing.

BioXcel Therapeutics (BTAI) is the latest company to prove it. The New Haven, Connecticut, biotech filed for Chapter 11 on Aug. 27, 11 weeks before the FDA is due to rule on an expanded label for its only approved product.

BioXcel filed Chapter 11 before its FDA decision, as Nasdaq suspends BTAI Sept. 8.AndreyPopov / Getty Images

Why BioXcel’s debt schedule beat its FDA catalyst

BioXcel makes Igalmi, a film placed under the tongue to treat acute agitation in adults with schizophrenia or bipolar disorder. The FDA approved it in April 2022 for supervised medical settings, and the company is waiting on an application to let patients use it at home. That decision is due Nov. 14, according to BioXcel’s Aug. 28 announcement.

Two weeks after that 2022 approval, BioXcel signed a financing package with funds affiliated with Oaktree Capital Management and the Qatar Investment Authority. The money was raised against a launch.

More Bankruptcy Coverage:

50-year-old theme and water park to close forever after summer season

Loss of Costco deal helps push beverage brand into Chapter 11

39-year-old ammunition manufacturer files Chapter 11 bankruptcy

The launch never happened at scale. Product revenue never topped $2.3 million in any year, and in 2025 it came in at $600,000, down 72%, while the net loss widened to $69.9 million, per the company’s annual report.

Cutting the sales force to preserve cash then made the revenue problem worse, the loop small drug companies rarely escape.

Meanwhile the debt did what debt does. Pricing moved to a fixed 13%, and quarterly amortization of 5% of principal kicked in at the end of March 2026.

The credit agreement was amended 14 times between November 2023 and August 2026, according to BioXcel’s SEC filings.

Read that number again. Fourteen amendments. Each one bought a few more months and cost a little more control.

Related: BofA makes bullish call on newly public biotech stock

By July the lenders required a “definitive strategic transaction on terms acceptable to them,” plus a committee with exclusive authority over any sale, per the July 3 amendment.

The 14th amendment, signed Aug. 24, three days before the filing, advanced $1.25 million of bridge money against a $250,000 upfront fee. That is 20% of the new principal, charged for three days of runway.

That is not a lender extending a lifeline. That is a lender steering.

What Teva is actually paying for BioXcel

Teva Pharmaceuticals (TEVA) signed on as stalking horse bidder for substantially all of BioXcel’s assets. The floor bid is $57.5 million in cash at closing, plus up to $67.5 million tied to how fast the at-home application clears, according to BioXcel’s Aug. 28 filing.

Those milestones price the remaining life of this company almost to the month:

Approval by Nov. 21, one week after the target date, pays the full $67.5 million, per Fierce Biotech. 

Approval by Feb. 28, 2027, drops the payment to $55 million, per the same report

Approval by May 31, 2027, drops it to $20 million, according to the asset purchase agreement filed with the court. 

Approval by Nov. 30, 2027, pays $5 million, per the same agreement

Do the arithmetic. Top rung to bottom, the value Teva assigns to BioXcel’s timeline falls $62.5 million over roughly 12 months, about $5.2 million for every month the agency takes.

Only one of those payments is ever made, and separate sales milestones apply only if approval slips past February 2027. That caps the deal at $125 million, not $145 million.

The payments also run solely on the at-home version, so today’s hospital sales of Igalmi earn the estate nothing. And Teva has no obligation to chase any milestone, with no efforts standard attached, per the filed agreement.

The deal gives the company “a clear framework to pursue a value-maximizing transaction,” Chief Executive Vimal Mehta said in the announcement.

Competing bids are due Oct. 9, with an auction Oct. 14 and a targeted closing Oct. 26, per the bidding procedures motion. A rival has to clear $60.2 million in cash just to be heard.

What the Nasdaq delisting means if you own BTAI

This is the part that matters most to individual holders, and it is already happening.

Nasdaq notified BioXcel on Aug. 31 that it will delist the stock over the Chapter 11 filing. Trading is suspended at the open Sept. 8, and the company will not appeal, according to BioXcel’s Sept. 1 filing.

Shares are expected to move to the Pink Limited Market, which the company acknowledges is a far thinner venue that could push the price down further.

Sept. 4 was the last regular Nasdaq session, with markets closed Sept. 7 for Labor Day. If you planned to decide next week, the exchange decided for you.

Now the math. About $112 million was outstanding to the Oaktree-affiliated lenders when BioXcel filed, and the bankruptcy loan approved on top of that runs to $77.25 million, only $19 million of it new cash.

Against that, the stalking horse pays $57.5 million at closing.

You do not need a restructuring background to finish the sentence. The cash on the table does not cover the secured debt, let alone the roughly $17 million of trade and professional claims behind it. Barring a bidding war, common shareholders get nothing.

That is the standard order in Chapter 11. Secured lenders first, unsecured creditors second, equity last.

The lesson for small-cap biotech investors

BioXcel called itself an artificial intelligence company and earned the label. It screened existing molecules for new uses and got a real FDA approval out of it, which is more than most AI drug-discovery stories can claim.

None of that saved it, and the reason is boring. The balance sheet had a schedule, and the science did not.

In my analysis of small-cap credit agreements, the amendment count is the most underused warning sign retail investors have, and it is free to check. When you hold a small cap that is one approval away, ask three questions before you add.

When does the debt mature or amortize, and is that before or after the catalyst? BioXcel’s loans matured April 2027 and amortization started March 2026. The money ran out in the gap.

How many times has the credit agreement been amended? The 8-K trail will tell you. One amendment is housekeeping. Fourteen is a company living quarter to quarter at its lenders’ pleasure.

How much debt sits ahead of you, and what would a buyer pay? When I lined those two numbers up here, the second came in smaller, which makes the shares an option on a bidding war rather than a claim on a business.

One more thing is worth sitting with. In June 2023, BioXcel disclosed that an outside investigator on a key trial had fabricated emails to the FDA. An audit cleared the data, but the stock fell roughly 64% in a day and never again raised equity on decent terms.

Three years later, a company that may be weeks from an FDA approval is selling itself for less than it owes.

Watch two dates from here. The Oct. 9 bid deadline tells you whether anyone besides Teva wants these assets. The Nov. 14 FDA date tells you what they were worth.

The drug might still work. The trade already did not.

Related: Bank of America sees major upside in this biotech stock

Real Madrid manager Jose Mourinho will make changes to his starting XI and face a familiar foe in the Champions League on Tuesday night at the Bernabeu in Inter Milan.

Futures on the Dow were significantly worse than the S&P 500 because of a cardiovascular drug’s late-stage setback.

Investing in quality dividend stocks offers you a chance to benefit from a steady stream of passive income and long-term capital gains. 

“Dividends can improve your performance by a third without doing anything,” Sam Stovall, chief investment strategist at CFRA, told CNBC. He noted that since 1945, reinvested dividends have made up roughly a third of the S&P 500’s total return.

Given this backdrop, let’s see if it makes sense to invest in Nike stock right now, which offers a tasty yield of 4.3%. 

Given that dividend yields and share prices are inversely related, investors should note that Nike is down 80% from all-time highs and trades at a 12-year low. 

Here is what it would take to turn Nike stock into a $ 1,000-a-year dividend paycheck.

Why Nike stock’s dividend yield jumped to 4.3%

Nike shares trade around $38.40 today, down almost 80% from the stock’s record highs. It is a brutal stretch for anyone who bought Nike stock in 2021. 

When a stock price falls significantly while the dividend increases steadily, the yield becomes attractive. 

Nike currently pays an annual dividend of $1.64 per share. Divide that by the current share price, and you get a forward yield of about 4.3%.

Related: Warren Buffett’s biggest bet has a dividend secret

For context, that is well above what Nike investors have historically collected, and it is a much richer payout than most large consumer brands offer today.

Wall Street is split on whether the stock drop is a buying opportunity or a warning sign. According to a CNBC report:

Truist Securities analyst Joseph Civello downgraded Nike to Hold from Buy in late August, cutting his price target to $42 from $47. 

Civello explained that a disappointing update from Dick’s Sporting Goods signals incremental murkiness around the footwear giant’s turnaround progress.

The analyst said it is best to move to the sidelines until there is more clarity around both the cleanup process.

How many Nike shares do you need for $1,000 in dividends?

The math here is simple once you have the numbers.

Nike pays $1.64 per share every year. To collect $1,000 in annual dividend income, divide $1,000 by $1.64. That comes out to about 610 shares.

At the current price of $38.40 per share, buying 610 shares of Nike would cost roughly $23,430.

That is the trade-off with a higher-yielding stock like Nike right now. The payout looks attractive, but investors are also buying a company in the middle of a turnaround, not a steady compounder trading near its highs.

Nike dividend ratios investors should watch

Before buying any dividend stock, it helps to look past the headline yield. Here are the key numbers for Nike right now, based on the company’s fiscal 2026 fourth quarter results:

Forward dividend yield: About 4.3%, based on a $38.40 share price

Annual dividend per share: $1.64

Approximate quarterly dividend: $0.41 per share

Annual dividend expense: $2.43 billion

Estimated FCF for fiscal 2027: $3.04 billion

Payout ratio: Around 80%. 

20-year dividend growth CAGR: 12.3%

Nike is projected to improve its free cash flow from $2.18 billion in fiscal 2026 to $3.04 billion in fiscal 2027 and $3.35 billion in 2028. 

An improving payout ratio should translate to consistent dividend hikes, if Nike can successfully execute its turnaround. 

Nike President and CEO Elliott Hill bets on a strategic turnaroundBloomberg / Getty Images

Is Nike stock a buy for dividend investors?

Nike’s underlying business is mixed right now, which is why the stock has struggled.

On the fiscal 2026 fourth-quarter earnings call, CEO Elliott Hill said Nike Running delivered five straight quarters of double-digit growth, adding roughly $1 billion to the business and gaining five points of market share in Western Europe and North America. 

Wholesale revenue also grew 4% for the full year, led by double-digit growth in North America.

The weak spots are Nike Sportswear and Jordan streetwear, which together make up about half of Nike’s revenue. 

More Retail:

Home Depot is making a big bet on cautious consumers

Another state just banned a controversial retail pricing practice

JPMorgan just flagged a slow-build food crisis

Hill said both are expected to remain negative through fiscal 2027, with improvement expected only in the back half of the year. 

Greater China revenue fell 17% in the fourth quarter alone, though executives said inventory cleanup and full-price selling are showing early signs of progress.

“Our teams in China are executing a comprehensive reset, returning to sport and innovation, taking a more local approach to product creation, and building a territory-level offense,” Hill stated. “At the same time, we’re reimagining how we operate in the marketplace.”

CFO Matt Friend said Nike expects gross margin to start expanding again in the first quarter of fiscal 2027, driven by cost cuts already made to the supply chain rather than sales growth alone.

For income-focused investors, Nike offers a real yield that is hard to find elsewhere in the sector. 

But the payout ratio against underlying cash flow, combined with a business still working through a turnaround, means this dividend deserves close monitoring rather than a set-it-and-forget-it purchase.

Related: Down almost 80%, is Nike stock undervalued or a value trap?

TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission.

Why we love this deal

Commuting every day in a car isn’t just time-consuming, but it can also be expensive. If you live in a condensed area, like a busy suburb or city, you have more options than just a car or a bus. An electric scooter is a fantastic option to travel around town, whether you’re heading to work or to the convenience store. Using one can help cut down on commute time, save money on fuel, and allow you to enjoy the outdoors while you ride. And the best part is it doesn’t require any effort like a bike or traditional scooter would. 

Right now, Walmart is having a big Flash sale on a ton of electric scooters. The Zdza Peak 750W Electric Scooter is one of them, and it’s on sale for only $207. Originally $410, it’s 50% off during a limited-time Flash deal.

Zdza Peak 750W Electric Scooter, $207 (was $410) at Walmart

Courtesy of Walmart

Shop at Walmart

Why do shoppers love it?

This powerful scooter is equipped with a 750-watt motor and four speed modes. For leisurely rides, you can use its lowest speed mode of just 3 miles per hour, but if you need a boost, it can reach an impressive 20 miles per hour. With a wide speed range, you can get to your destination quickly and efficiently. 

The e-scooter can go the distance, too. In just one charge, it can travel 15 to 20 miles. That’s more than enough to get you to and from work if you’re a daily commuter. It’s also great for college students who need to make it across campus, from class to class. 

Not only is this scooter efficient, but it also has added features that make it safe to use. It has a dual braking system, headlights, taillights, and turn signals, all highly useful additions that will make you feel safe when you hit the road. 

At 37 pounds, it’s lightweight and easy to carry. And with a foldable design, it’s easy to store under your desk at the office or in the trunk of your car.

Related: Walmart is selling a $700 electric bike that goes 20 MPH for 43% off

Details to know

Max speed: Up to 20 miles per hour.

Range per charge: 15 to 20 miles.

Weight capacity: 264 pounds.

Walmart shoppers said this scooter is “well-built” and a great form of transportation, whether you’re commuting or need an easy way to get from point A to point B. In fact, a customer said it’s easier than riding a bike. One shopper said the “battery lasts a long time,” and the “speed is perfect” for daily use. Another reviewer said the speed is “fast enough for suburban roads.”

Many shoppers noted that the little details make it that much better and easier to use, like turn signals, a bell, and a headlight. While reviewers say it “rides pretty smooth,” some note that it doesn’t have shock absorbers and recommend avoiding noticeable bumps in the road.

Shop more deals

5th Wheel 350W Electric Scooter, $169 (was $269) at Walmart

Mihover 550W Pet-Friendly Electric Scooter with Seat, $340 (was $500) at Walmart

iScooter Electric Scooter, $214 (was $290) at Walmart

The Zdza Peak 750W Electric Scooter is on sale for only $207 after a 50% discount, and it’s a great buy for commuters, students, and more.

Real Madrid vice-captain Vinicius Jr. promised that his team will win a record-extending 16th Champions League title this season.

With three weeks remaining in the Major League Baseball season, there are 4 excellent National League teams hoping to cash their ticket for a Wild Card berth.

Find out why Bryce Harper and Drake Baldwin have the most alluring home run bets on Tuesday’s 15-game MLB slate, with both boasting longer than +400 odds.

Earlier on Monday, Trump threatened to ban the sale of Bombardier’s planes in the U.S., calling them not “good enough,” amid an escalating trade fight with Canada.